Poxel S.A.

EPA:POXEL.PA

0.53 (EUR) • At close September 18, 2024
Bedrijfsnaam Poxel S.A.
Symbool POXEL.PA
Munteenheid EUR
Prijs 0.53
Beurswaarde 28,052,455
Dividendpercentage 0%
52-weken bereik 0.297 - 0.95
Industrie Biotechnology
Sector Healthcare
CEO Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D.
Website https://www.poxelpharma.com

An error occurred while fetching data.

Over Poxel S.A.

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for

Vergelijkbare Aandelen

Valbiotis SA logo

Valbiotis SA

ALVAL.PA

1.332 EUR

ABIONYX Pharma SA logo

ABIONYX Pharma SA

ABNX.PA

1.25 EUR

Crossject Société Anonyme logo

Crossject Société Anonyme

ALCJ.PA

2.375 EUR

Visiomed Group SA logo

Visiomed Group SA

ALVMG.PA

0.173 EUR

GeNeuro SA logo

GeNeuro SA

GNRO.PA

0.065 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)